Representative Jefferson Shreve (R-Indiana) recently bought shares of Elevance Health, Inc. NYSE: ELV. In a filing disclosed on March 09th, the Representative disclosed that they had bought between $15,001 and $50,000 in Elevance Health stock on February 24th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Purchased $15,001 - $50,000 in shares of RTX NYSE: RTX on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of Royal Gold NASDAQ: RGLD on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of QUALCOMM NASDAQ: QCOM on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 2/24/2025.
- Sold $15,001 - $50,000 in shares of Norfolk Southern NYSE: NSC on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 2/24/2025.
- Purchased $50,001 - $100,000 in shares of AbbVie NYSE: ABBV on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of Johnson & Johnson NYSE: JNJ on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of The Cigna Group NYSE: CI on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of Adobe NASDAQ: ADBE on 2/24/2025.
Elevance Health Stock Performance
ELV stock traded down $8.37 on Wednesday, hitting $413.67. The company's stock had a trading volume of 809,784 shares, compared to its average volume of 1,632,357. The company has a current ratio of 1.45, a quick ratio of 1.50 and a debt-to-equity ratio of 0.71. The stock has a market cap of $94.05 billion, a price-to-earnings ratio of 16.14, a price-to-earnings-growth ratio of 1.18 and a beta of 0.86. Elevance Health, Inc. has a 1 year low of $362.21 and a 1 year high of $567.26. The firm has a 50 day moving average of $392.54 and a two-hundred day moving average of $431.56.
Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. Equities analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.
Elevance Health Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th will be given a dividend of $1.71 per share. The ex-dividend date of this dividend is Monday, March 10th. This is a positive change from Elevance Health's previous quarterly dividend of $1.63. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.65%. Elevance Health's dividend payout ratio (DPR) is 26.71%.
Insider Buying and Selling
In related news, CAO Ronald W. Penczek sold 443 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $415.13, for a total value of $183,902.59. Following the sale, the chief accounting officer now owns 1,847 shares of the company's stock, valued at $766,745.11. The trade was a 19.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $396.30, for a total value of $1,388,635.20. Following the completion of the sale, the executive vice president now owns 10,116 shares in the company, valued at $4,008,970.80. This trade represents a 25.73 % decrease in their position. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
ELV has been the subject of several research analyst reports. StockNews.com raised Elevance Health from a "hold" rating to a "buy" rating in a research note on Saturday, March 1st. Cantor Fitzgerald reissued an "overweight" rating and issued a $485.00 target price on shares of Elevance Health in a research note on Friday, January 24th. Stephens lowered Elevance Health from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $520.00 to $440.00 in a research note on Wednesday, January 22nd. Barclays increased their target price on Elevance Health from $501.00 to $512.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Finally, Truist Financial dropped their target price on shares of Elevance Health from $520.00 to $480.00 and set a "buy" rating on the stock in a report on Monday, January 6th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $517.03.
Read Our Latest Research Report on ELV
Institutional Trading of Elevance Health
Hedge funds and other institutional investors have recently made changes to their positions in the business. Accredited Wealth Management LLC bought a new stake in shares of Elevance Health during the 4th quarter worth approximately $25,000. Raelipskie Partnership acquired a new position in Elevance Health in the 3rd quarter valued at $26,000. Flagship Wealth Advisors LLC bought a new position in Elevance Health during the fourth quarter worth about $26,000. OFI Invest Asset Management acquired a new stake in Elevance Health during the fourth quarter worth approximately $29,000. Finally, WealthTrak Capital Management LLC bought a new position in shares of Elevance Health in the fourth quarter worth $29,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
Elevance Health Company Profile
(
Get Free Report)
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Featured Articles
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
